| Cas No.: | 1025504-45-3 |
| Chemical Name: | (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl L-valinate |
| Synonyms: | NBI-98854; NBI 98854; NBI98854; MT-5199; MT 5199; MT5199; Valbenazine; Ingrezza; |
| SMILES: | N[C@@H](C(C)C)C(O[C@H]1[C@H](CC(C)C)CN2CCC3=CC(OC)=C(OC)C=C3[C@@]2([H])C1)=O |
| Formula: | C24H38N2O4 |
| M.Wt: | 418.578 |
| Purity: | >98% |
| Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Description: | Valbenazine is a prodrug of the (+)-α isomer of tetrabenazine for tardive syndrome therapy, and inhibits VMAT2 function. |
| In Vivo: | Valbenazine shows a distinctive improvement in tardive dyskinesia symptoms during the successful Phase II trial[1]. |
| References: | [1]. Müller T, et al. Valbenazine granted breakthrough drug status for treating tardive dyskinesia. Expert Opin Investig Drugs. 2015 Jun;24(6):737-42. |
MSDS
COA
| LOT NO. | DOWNLOAD |
|
|
|
| 2018-0101 |
|
| 2018-0101 |
|